Table 3. Analysis of Associations Between OPRD1 Genetic Variants and Treatment Outcome in Opioid-dependent African-Americans.
| SNP ID | Minor allele | MAF | Position | Beta 1—methadone | P-value—methadone | Beta 2—buprenorphine | P-value—buprenorphine | P-value—G × E |
|---|---|---|---|---|---|---|---|---|
| rs678849 | T | 0.26 | Chr1:29145188 | 0.2151 | 0.067 | −0.2652 | 0.0043 | 0.00081 |
| rs10753331 | A | 0.39 | Chr1:29164582 | 0.07416 | 0.48 | 0.00481 | 0.96 | 0.62 |
| rs529520 | G | 0.33 | Chr1:29174946 | 0.08214 | 0.44 | −0.1134 | 0.28 | 0.19 |
| rs581111 | C | 0.34 | Chr1:29175373 | 0.1428 | 0.17 | 0.01698 | 0.84 | 0.34 |
| rs2234918 (G307G) | T | 0.33 | Chr1:29189597 | 0.1615 | 0.070 | 0.02902 | 0.76 | 0.29 |
Abbreviations: G × E, gene × environment; MAF, minor allele frequency.
P-values were generated by linear regression for the individual treatment groups, as well as gene × environment analyses with treatment group as a covariate. The residue number and encoded amino acids of the synonymous variant is included after the SNP ID.